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Medicine and Surgery, Federico II University. PAbstract Background and aims: Potential beneficial effect of probiotic yogurt on the lipid profile
has raised much interest. However, the results are inconsistent in this regard. The aim of the
study is to determine the effects of probiotic yogurt on serum lipid profile in individuals with
mild to moderate hypercholesterolemia.
Methods and results: Online databases including PubMed, Scopus, ISI Web of Science, Cochrane
Central Register of Controlled Trials, Science Direct, Google Scholar and Igaku Chuo Zasshi were
searched until March 19th 2019. The effect sizes were expressed as the weighted mean difference
(WMD) with 95% confidence interval (CI). Seven eligible trials with 274 participants were
included in this systematic review. Pooling of 9 effect sizes from these seven articles revealed
a significant reduction in total cholesterol and low density lipoprotein cholesterol levels
following probiotic yogurt consumption (mean difference: 8.73 mg/dl, 95% CI: 15.98, 1.48,
p-value Z 0.018 and mean difference: 10.611 mg/dl, 95% CI: 16.529, 4.693, p-
value Z 0.000, respectively) without significant heterogeneity among the studies (I2 Z 40.6%,
p-value Z 0.1 and I2 Z 24.2%, p-value Z 0.229, respectively). The results showed no significant
changes in high density lipoprotein cholesterol and triglyceride levels. Also, none of the variables
showed a significant change for sensitivity analysis.
Conclusion: Available evidence suggests that probiotic yogurt can significantly reduce total
cholesterol and LDL-c in subjects with mild to moderate hypercholesterolemia without a signif-
icant effect on HDL-c and triglyceride levels.
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Hypercholesterolemia is a major risk factor for lifestyle-
related diseases such as atherosclerosis and cardiovascular
diseases (CVDs), including coronary heart disease (CHD)
and stroke [1]. In fact, the possibility of heart attack is
three times higher in individuals with hypercholesterole-
mia than those with normal blood lipid profile [2]. Overall,
raised cholesterol is estimated to cause 2.6 million deaths
(4.5% of total) and 29.7 million disability adjusted life years
(DALYS), or 2.0% of total DALYS [3]. Each 1% reduction of
the cholesterol level has been said to result in 2.3%
reduction of the coronary related risks [4]. A 10% reduction
in serum cholesterol in men aged 40 has been reported to
result in a 50% reduction in heart diseases within 5 years
[3]. Statins are commonly accepted as a treatment of
choice for lowering low-density lipoprotein (LDL) choles-
terol, reducing coronary heart disease morbidity and
mortality [5]. However, many patients have potential in-
dications for non-pharmacological treatment of dyslipi-
demia, including adults with medium-to-low
Cardiovascular (CV) risk and mild dyslipidemia, dyslipi-
demic children-adolescents with a family history of pre-
mature CV disease, dyslipidemic adults intolerant to drugs
because of the side effects, and adults with human im-
munodeficiency virus (HIV) infection and mild dyslipide-
mia [6]. As adherence to medications for treatment of a
symptomless condition such as high LDL-c levels is
important, factors leading to the risk for non-adherence to
medications such as fear of drug-drug interactions or side
effects of drugs, negative earlier experience with phar-
macological therapies, presence of psychological prob-
lems/cognitive impairments, ignoring the importance of
medication intake, medication acting as a reminder of the
patients’ condition or the compulsion to take medications,
and making the patient feel old or bad about themselves
should be taken into consideration. In the case of statins,
factors such as age, gender, income, and race which are the
causes of non-adherence should also be regarded [5,7].
Even in patients who are diagnosed with CVDs, adherence
to statin therapy often remains poor. Therefore, it is ad-
vantageous to identify non-drug treatments and use them
alone or in combination with drugs for the treatment of
hypercholesterolemia. Probiotic bacteria are defined by the
World Health Organization (WHO) as “live microorgan-
isms which when administered in adequate amounts
confer a health benefit on the host” [8]. In a report from
WHO (2001), no “acute negative effects” associated with
the consumption of probiotics has been mentioned [9].
Previously, several experimental and clinical studies re-
ported that probiotic bacteria such as Lactobacillus and
Bifidobacterium had beneficial effects on serum lipid
profile [10]. Although the findings on the lipid lowering
effect of probiotics in several human clinical studies are
controversial, some systematic reviews have supported
their hypolipidemic role based on randomized controlled
trials [10e16]. However, these reviews are often inconsis-
tent due to missing the required sub-group analyses[11,12,15], missing sub-group analysis based on the health
status of the subjects in terms of disease (diabetes melli-
tus, hypertension, non-alcoholic fatty liver, obesity and
overweight) as well as pregnancy, smoking and other
variables [10,13,14,16], absence of subgroup analysis in the
context of severity of hypercholesterolemia (mild to
moderate-severe) [10,14], and limitations of the quantity
and quality of the studies reviewed [10,11,15]. A number of
previous meta-analyses have conducted subgroup analysis
for probiotic dairy products in general and probiotic cap-
sules in particular [10,13,14,16]. However, milk, yogurt and
kefir have different constituents and the analyses of their
effects as a whole may create bias in detecting the real
effects of probiotics on serum lipid profile. For example the
contribution of probiotic bacteria in yogurt to the
improvement of intestinal micro-flora has been widely
recognized for their effectiveness, while these bacteria
should overcome the adverse effects of the low pH of
yogurt and antagonistic action of other fermenting flora
[17]. Moreover, we found some clinical studies reporting
the effects of probiotics, in the form of yogurt, on the lipid
profiles which were missed in the previous meta-analyses
[10,13,14,16]. Finally, because of intolerance to lactose, the
consumption of probiotics in the form of milk may not be
easily acceptable by everyone. Thus, it seems that daily
intake of probiotic yogurt alone or in combination with
drugs can be a better choice.
The purpose of this study was to evaluate the effects of
probiotic yogurt compared with ordinary yogurt on
lipid profiles in subjects with mild to moderate
hypercholesterolemia.Method
The current systematic review and meta-analysis followed
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [18] for every stage of
processing, analyzing, and reporting the data. The study
protocol is registered in the Prospective Register of Sys-
tematic Reviews (PROSPERO) [protocol code:
CRD42018097134].
Search strategy
We searched for electronically available research studies in
the PubMed/Medline, Scopus, ISI Web of Science, Cochrane
Central Register of Controlled Trials (CENTRAL), Science
Direct, Google Scholar and Igaku Chuo Zasshi databases to
identify relevant studies published before March 19th
2019, without language, time or any other restrictions. In
Igaku Chuo Zasshi database, the search was done both in
Japanese and in English languages. The type of article was
limited to randomized controlled trials (RCTs) or clinical
trials. The following keywords were used: ((probiotic*) OR
(Lactobacillus) OR (Bifidobacterium)) AND ((yogurt) OR
(yoghurt) OR (milk) OR (Kefir) OR (“fermented dairy”))
AND ((“total cholesterol”) OR (“LDL-c”) OR (“LDL
Probiotic yogurt, Lipid Profile, Hypercholesterolemia 13cholesterol”) OR (cholesterol) OR (“HDL-c”) OR (“HDL
cholesterol”) OR (“lipid profile”) OR (“lipid status”) OR
(“blood lipids”) OR (“cardiovascular disease”) OR (“heart
disease”) OR (lipid*) OR (triglyceride*)) AND ((hypercho-
lesterolemia) OR (“mildly hypercholesterolemia”) OR
(“moderately hypercholesterolemia”) OR (hypercholester-
olemic) OR (elevated cholesterol)) AND NOT ((rat) OR
(mouse) OR (animal) OR (rabbit) OR (hamster) OR
(“in vitro ”)).
Eligibility criteria
Screening the titles and abstracts, followed by the full texts
assessment of the eligible articles were performed by two
independent investigators (B.P & S.F). The inclusion criteria
in our meta-analysis were:
1 Clinical trials in which participants took probiotic
yogurt and lipid profiles (low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol,
total cholesterol and triglyceride) were then studied
too.
2 Studies in which participants were people with hyper-
cholesterolemia with no other illnesses and their Body
Mass Index (BMI) were less than 30.
3 Studies in which the criteria for mild to moderate hy-
percholesterolemia were addressed (total cholesterol:
200e300 mg/dl or 5.2e7.76 mmol/l).
Age limit and specific time frame were not considered
for search and all studies conducted on this topic by March
2019 were reviewed.
Exclusion criteria in this study were:
1 Animal and in vitro studies.
2 Studies investigating the effects of fermented yogurt,
without mentioning the dose and type of probiotic
bacteria.
3 Studies including pregnant or breast-feeding women or
individuals with certain diseases or those who had
previously undergone intestinal surgery.
4 Studies investigating the effect of probiotic supple-
mentation and probiotic milk but not probiotic yogurt.
5 Studies in which subjects were hypercholesterolemic
and normocholesterolemic, but the results for hyper-
cholesterolemic patients were not separated from the
results of normocholesterolemic subjects.
6 Studies using fermented milk as probiotic without
mentioning the word yogurt.
Data extraction and quality assessment
The studies were selected by two independent researchers
(B.P) and (S.F) on the basis of inclusion and exclusion
criteria. Any disagreement between researchers was
resolved by consulting the third researcher (F.SH). The
following information was collected: author’s name, study
location, study design, study population, mean age, sex,sample size, intervention group, control group, probiotic
dosage, probiotic strain, and period of intervention. This
information is shown in Table 1.Risk of bias assessment
The quality of the studies was independently evaluated by
2 researchers (B.P) and (S.F) according to the Cochrane
Handbook for Systematic Reviews of Interventions, version
5.1.0 [19] and by using the following criteria:
1 random sequence generation
2 allocation concealment
3 blinding of participants and personnel
4 blinding of outcome assessment
5 incomplete outcome data, and
6 selective outcome reporting.
There were six key domains according to which each
study was assigned in terms of overall risk of bias,
including low risk (low for all key domains), high risk
(high for one or more key domains.), and unclear risk
(unclear for one or more key domains).Statistical analysis
For all outcomes, the effect sizes were measured by the
mean difference between the intervention and the control
group at the follow-up. Where the effect size was not re-
ported, the difference in the mean values at the baseline
and at the end of the study were used. We extracted the
mean and Standard Deviation (SD) from the studies
reviewed and where the data were reported in a different
format. This method was used by Hozo et al. as follows:
SD Z square root [(SD pre-treatment) 2 þ (SD post-
treatment) 2 e (2R  SD pre-treatment  SD post-
treatment)] [20]. The groups were combined by applying
a weighted average when we had >1 control group, to
enable a single pairwise comparison. In order to estimate
effect sizes, the random effects model (DerSimonian and
Laird method) was used and the results were provided
across weighted mean difference (WMD) and 95% confi-
dence interval (CI). We used Plot digitizer software when
the results were only presented in the graphic form. Het-
erogeneity was calculated by the I2 index [21]. We
considered I2 index of greater than 50% as the substantial
heterogeneity among the trials. Subgroup analysis was
performed to identify factors for high heterogeneity. We
considered the values less or more than median as the cut
off values for each aforementioned quantitative parameter
of subgroups. The sensitivity analysis was done by using
the leave-one-out method [22] to examine the impact of
each study on the results. The funnel plot was used to
determine publication bias, by either Beggs’ rank correla-
tion or Eggers’ regression test. STATA version 11.0 was used
for statistical analysis (Stata Corp, College Station, TX) and
P values < 0.05 was considered statistically significant.
Table 1 Characteristics of the randomized clinical trials that were included in the systematic review.
Author (year)
(reference)
Country Clinical Trial
Design
Population Mean
Age (year)
Sex Sample Size
Case/Placebo
Intervention group Control group Probiotic
dose (cfu)
Probiotic strain Period
(week)
Xiao, J. Z et al.
(2003) [28]
Japan Parallel Healthy H.C 43.8 Male 16/16 Probiotic yogurt
(300 mg)
ordinary yogurt
(300 mg)
>10⁸ Bifidobacterium
longum strain
BL1
4
Kiessling, G et al.
(2002) [17]
Jena Cross-over Healthy
H.C
37 Female 14/14 Probiotic yogurt
(300 mg)
ordinary yogurt
(300 mg)
Lactobacillus.
(10⁶ e 10⁸)
B. longum
(>10⁵)
Lactobacillus
acidophilus 145,
Bifidobacterium
longum 913
7
Jones, M.L et al.
(2012) [8]
Canada Parallel Healthy
H.C
51.8 Both 56/58 Probiotic yogurt
(125 mg)
ordinary yogurt
(125 mg)
5  10⁹ Lactobacillus
reuteri (NCIMB
30242)
6
Baroutkoub, A et al.
(2010) [4]
Iran Cross-over Healthy
H.C
43.5 Both 46/46 Probiotic yogurt
(300 mg)
ordinary yogurt
(300 mg)
10⁶ L. acidophilus,
Bifidobacteria
6
Anderson, J.W et al.
(1999) [29]
Oklahoma Cross-over Healthy
H.C
58 Both 19/19 Probiotic yogurt
(200 mg)
ordinary yogurt
(200 mg)
>1  10⁷ Lactobacillus
Acidophilus L1
4
Ataie-Jafari. A et al.
(2009) [31]
Iran Cross-over Healthy
H.C
50.5 Both 14/14 Probiotic yogurt
(300 mg)
ordinary yogurt
(300 mg)
10⁶ Lactobacillus
acidophilus,
Bifidobacterium
lactis
6
Ataie-Jafari. A et al.
(2007) [30]
Iran Parallel Healthy
H.C
50.5 Both 8/6 Probiotic yogurt
(300 mg)
ordinary yogurt
(300 mg)
10⁶ Lactobacillus
acidophilus,
Bifidobacterium
lactis
6
14
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Study selection
A flow chart depicting the literature search and selection is
presented in Fig. 1. Using the key terms of the study, we
identified 125 articles through searching the databases
and four additional articles through other sources. First,
duplicate articles (n Z 37) were removed and then
another 80 articles, recognized to be irrelevant, were
removed by reading their titles and abstracts. Next, we
evaluated the full text of the remaining 12 articles from
which five articles were excluded for the following rea-
sons: 1- it was inaccessible article [23], 2- it did not
include individuals with mild to moderate hypercholes-
terolemia [24e26], and 3- the outcome of interest was not
reported [27]. The two reviewers (B.P) and (S.F) agreed on
the study screening procedure. Although we finallyRecords idenƟfied through 
database searching 
(n =125) 
Records aŌer duplicates remo
(n =92 ) 
Records screened
(n = 92  ) 
Full-text arƟcles assessed 
for eligibility 
(n =12 )
Studies included in 
qualitaƟve synthesis 
(n = 7  ) 
7 Studies included in 
quanƟtaƟve synthesis 
(meta-analysis) 
(Arms = 9 ) 
Figure 1 Flow chart of theanalyzed seven articles, two of them can be viewed as
separate trials. One of them was the study by Xiao et al.
(2003), which separately reported the results for people
with baseline total cholesterol > 200 mg/dl and those with
baseline total cholesterol > 240 mg/dl [28]. The other
study was performed by Anderson et al. applying two
intervention times. These last two studies can be regarded
as two independent studies [29]. Therefore, seven articles
were included in this systematic review with the effect
sizes of 9.Study and participant characteristics
The characteristics of the studies included in the pre-
sent systematic review and meta-analysis are shown in
Table 1. Three studies were conducted in Iran [4,30,31]
and the others were conducted in Japan [28], GermanyAddiƟonal records idenƟfied 
through other sources 
(n =4 ) 
ved 
Records excluded 
(n = 80  )
Full-text arƟcles excluded, 
with reasons 
(n =5 )  
Inaccessible arƟcle(n=1)
[23]
 Did not report outcome 
of interest(n=1) [27]
The populaƟon studied is 
non-target(n=3) [24-26]
study selection process.
16 B. Pourrajab et al.[17], Canada [8] and the U.S.A [29]. From the total seven
studies, four studies were crossover in design and con-
sisted of 93 participants [4,17,29,31] The intervention
period was six weeks in four studies [4,8,30,31], four
weeks in two studies [28,29] and seven weeks in one
study [17]. In the majority of trials, the daily consumption
of probiotic yogurt in subjects was 300 mg/d and in one
study it was 125 mg/d [8]. The probiotic dosage was 10⁶
cfu in three of the studies [4,30,31] and it was >10⁷cfu
[29], >10⁸cfu [28], 10⁶ e 10⁸cfu [17], and >10⁹cfu in the
rest of the studies [8]. All the studies used ordinary yogurt
as placebo which was similar in dose to probiotic yogurt.
The majority of included studies consisted of both gen-
ders whereas one study was performed merely on male
adults [28] and one study on female individuals [17]. The
age range of the participants was 37e58 years old in these
studies.Risk of bias assessment
As shown in Table 2, except for one study that was
assessed as high risk in random sequence generation [4],
the other studies were randomized, but did not explicitly
mentioned the random sequence generation methods;
therefore, they were regarded as unclear risk of bias
[8,17,28e31]. One study was assessed as high risk in allo-
cation concealment [4], and six as unclear risk
[8,17,28e31]. There were two studies which were double-
blind randomized controlled trials (RCTs) and were thus
considered as low risk of bias for blinding of participants
and personnel [8,29]. There were also five studies with
single blind trials which were therefore considered as
unclear risk of bias [4,17,30,31,28]. None of the trials pro-
vided a clear description of blinding of outcome assess-
ment and other issues. Two studies provided incomplete
outcomes [8,28] and five articles were not clear on this
matter [4,17,29e31]. One study was assessed as high risk in
selective reporting [4], two as unclear on risk [8,30], and
the other four studies as low risk of bias
[17,28,29,31]. Except for one study that was assessed as
high risk in quality [4], Since the other studies were
considered as unclear risk of bias for at least one of the six
key domains, we found the quality of these studies “un-
clear” [8,17,28e31].Table 2 Risk of bias assessment according to the Cochrane collaboration
Study, Year (reference) Random
sequence
generation
Allocation
concealment
Blindi
partic
and p
Xiao, J. Z et al. (2003) [28] Unclear Unclear Uncle
Kiessling, G et al. (2002) [17] Unclear Unclear Uncle
Jones, M.L et al. (2012) [8] Unclear Unclear Low
Baroutkoub, A et al. (2010) [4] High High Uncle
Anderson, J. W et al. (1999) [29] Unclear Unclear Low
Ataie-Jafari, A
Et al. (2009) [31]
Unclear Unclear Uncle
Ataie-Jafari, A et al. (2007) [30] Unclear Unclear UncleMeta-analysis
Total cholesterol (TC)
There were seven studies with 352 participants
(caseZ 179, and controlZ 173) which reported TC, LDL-c,
HDL-c and triglyceride as an outcome measure. Combined
results of the random-effects model showed a significant
reduction in TC following the probiotic yogurt consump-
tion (MD: 8.73 mg/dl, 95% CI: 15.98,-1.48, p Z 0.018)
without a significant heterogeneity among the studies
(I2 Z 40.6%, p Z 0.1) (Fig. 2). Subgroup analysis for dura-
tion of intervention showed that the reduction of TC was
significantly higher in participants with intervention
duration of >4 weeks (WMD Z 14.210; 95% CI:-24.609,
3.812; P Z 0.007) and in those receiving probiotic
yogurt with the dose of 300 mg/d (WMD Z 12.400,
95% CI, 21.116, 3.684; P Z 0.005). However, no associ-
ation was observed in participants with intervention
duration of 4 weeks and in those receiving probiotic
yogurt with the dose of <300 mg/d (see Table 3). Sensi-
tivity analysis indicated that no study reported a signifi-
cant impact on the overall effect sizes of TC (Supplemental
Fig. 1). Assessment of publication bias by visual inspection
of funnel plot did not show any evidence of publication
bias in the meta-analysis of probiotic yogurt consumption
on TC (p Z 0.364) (Supplemental Fig. 2).
High Density Lipoprotein cholesterol (HDL-c)
Combined results of the random-effects model showed no
significant increase in HDL-c following probiotic yogurt
consumption (MD: 1.567 mg/dl, 95% CI: 1.586, 4.719,
p Z 0.330) and no significant heterogeneity among the
studies (I2 Z 28.0%, p Z 0.19) (Fig. 3). Sensitivity analysis
revealed that no study had a significant impact on the
overall effect sizes of HDL-c (Supplemental Fig. 1).
Assessment of publication bias by visual inspection of
funnel plot did not show any evidence of publication bias
in the meta-analysis of probiotic yogurt consumption on
HDL-c (p Z 0.991) (Supplemental Fig. 2).
Low Density Lipoprotein cholesterol (LDL-c)
Combined results of the random-effects model showed a
significant reduction in LDL-c following probiotic yogurt
consumption (MD: 10.611 mg/dl, 95% CI: 16.529,
4.693, p Z 0.000) without a significant heterogeneity’s risk of bias assessment tool.
ng of
ipants
ersonnel
Blinding of
outcome
assessment
Incomplete
outcome
data
Selective
reporting
Overall
assessment
of risk of bias
ar Unclear Low Low Unclear
ar Unclear Unclear Low Unclear
Unclear Low Unclear Unclear
ar Unclear Unclear High High
Unclear Unclear Low Unclear
ar Unclear Unclear Low Unclear
ar Unclear Unclear Unclear Unclear
Table 3 Subgroup analyses of a probiotic yogurt consumption on serum Total cholesterol, LDL-c, HDL-c and TG levels.
No. I2(%) p-heterogeneity
intergroup
WMD (95% CI)
(weighted mean difference)
Significance
test (Pvalue)
Total cholesterol 9 40.6 0.1 8.734 (15.986, 1.481) 0.018
Time(week)
4 4 34.7 0.20 4.165 (13.216, 4.886) 0.36
>4 5 34.5 0.21 14.210 (24.609, 3.812) 0.007
Yogurt dose(mg/day)
300> 3 51.8 0.126 2.195 (15.315, 10.924) 0.743
300 6 32.3 0.193 12.400 (21.116, 3.684) 0.005
Age(year)
<50 years old 4 8 0.35 7.957 (16.355, 0.441) 0.063
50 years old 4 69.4 0.02 9.039 (25.709, 7.631) 0.28
NR 1 _ _ 12.480 (24.037, 0.923) 0.034
HDL-c 9 28 0.196 1.567 (-1.586, 4.719) 0.330
Time(week)
4 4 0 0.927 0.968 (-3.481, 5.417) 0.670
>4 5 62 0.032 2.033 (-3.394, 7.461) 0.463
Yogurt dose(mg/day)
300> 3 0 0.997 2.146 (-1.891, 6.184) 0.297
300 6 54.4 0.052 1.219 (-3.940, 6.378) 0.643
Age(year)
<50 years old 4 59 0.062 3.147 (-3.657, 9.951) 0.365
50 years old 4 _ 0.483 0.236 (4.395, 3.924) 0.912
NR 1 0 _ 2 (-3.482, 7.482) 0.475
LDL -c 9 24.2 0.229 10.611 (-16.529, -4.693) 0.000
Time(week)
4 4 0 0.968 4.190 (11.175, 2.795) 0.024
>4 5 0 0.467 16.773 (23.228, 10.317) 0.000
Yogurt dose(mg/day)
300> 3 24.8 0.264 9.981 (16.599, 4.693) 0.016
300 6 35.5 0.163 12.026 (21.696, 2.356) 0.015
Age(year)
<50 years old 4 50.4 0.109 9.155 (21.523, 3.214) 0.147
50 years old 4 0 0.398 8.972 (18.237, 0.294) 0.058
NR 1 _ _ 14.820 (22.540, 7.100) 0.000
TG 9 5.5 0.390 4.524 (-10.101, 19.148) 0.544
Time(week)
4 4 0 0.713 1.774 (20.882, 24.429) 0.878
>4 5 42.5 0.138 0.306 (26.734, 26.121) 0.982
Yogurt dose(mg/day)
300> 3 0 0.925 24.585 (3.16, 45.559) 0.022
300 6 0 0.795 10.458 (29.309, 8.393) 0.277
Age(year)
<50 years old 4 0 0.500 10.566 (31.481, 10.349) 0.322
50 years old 4 0 0.805 6.891 (20.966, 34.748) 0.628
NR 1 _ _ 27.590 (1.878, 53.302) 0.035
Probiotic yogurt, Lipid Profile, Hypercholesterolemia 17among the studies (I2 Z 24.2%, p Z 0.229) (Fig. 4).
Sensitivity analysis indicated that no study had a signifi-
cant impact on the overall effect sizes of LDL-c
(Supplemental Fig. 1). Assessment of publication bias by
visual inspection of funnel plot did not show any evidence
of publication bias in the meta-analysis of probiotic yogurt
consumption on LDL-c (p Z 0.830) (Supplemental Fig. 2).
Triglyceride (TG)
Combined results of the random-effects model showed no
significant reduction in TG following probiotic yogurt
consumption (MD: 4.524 mg/dl, 95% CI: 10.101, 19.148,
p Z 0.544) and no significant heterogeneity among the
studies (I2 Z 5.5%, p Z 0.390) (Fig. 5). Sensitivity analysis
indicated that no study reported a significant impact on
the overall effect sizes of TG (Supplemental Fig. 1).
Assessment of publication bias by visual inspection offunnel plot did not show any evidence of publication bias
in the meta-analysis of the effect of probiotic yogurt con-
sumption on TG (p Z 0.068) (Supplemental Fig. 2).Discussion
This meta-analysis systematically reviewed seven ran-
domized controlled trials which had examined the effect
of probiotic yogurt on serum lipid profile in mild to
moderate hypercholesterolemic individuals. To our
knowledge, this is the first meta-analysis investigating this
topic. Results of our analysis showed that serum total
cholesterol and LDL-c levels significantly decreased in the
group receiving probiotic yogurt as compared with the
control group. However, the effect of probiotics on HDL-c
and triglyceride was not statistically significant.
Figure 2 Forest plot of randomized controlled trials investigating the effects of probiotic yogurt on total cholesterol.
Figure 3 Forest plot of randomized controlled trials investigating the effects of probiotic yogurt on HDL-c.
18 B. Pourrajab et al.Considering the association between probiotic yogurt and
serum lipid profile, our findings are similar to those of
previous meta-analyses of randomized controlled trials
[10e16]. A previously conducted meta-analysis by Larsen
et al. [11] has reported reductions in total cholesterol
(8.51 mg dl) and LDL-c (7.74 mg dl) levels afterconsumption of probiotic yogurt. Another study per-
formed by Guo et al. [12] has showed that subjects
receiving probiotic yogurt had a significantly lower total
cholesterol (6.40 mg dl) and LDL-c (4.90 mg dl)
compared to controls. Moreover, Cho et al. [13] have
remarked that the pooled mean net change in total
Figure 4 Forest plot of randomized controlled trials investigating the effects of probiotic yogurt on LDL-c.
Figure 5 Forest plot of randomized controlled trials investigating the effects of probiotic yogurt on Triglyceride.
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20 B. Pourrajab et al.cholesterol and in LDL-c were 7.8 mg/dl and 7.3 mg/dl,
respectively for those treated with probiotic yogurt. Shi-
mizu et al. [10] have discussed that probiotic intervention
causes significant changes in total cholesterol
(MD Z 0.17 mmol/l) and LDL-c (MD Z 0.22 mmol/l).
Similarly, Jing Suna et al. [14] have showed that the pooled
effect of total cholesterol and LDL-c were - 0.27 mmol/l
and - 0.23 mmol/l, respectively in the probiotic group
compared with the control group. Finally, Wang et al. [16]
have showed that the total cholesterol level significantly
reduced in probiotics group (MD Z 13.27).
Our results about HDL-c and triglyceride are similar to
the findings of the above mentioned studies which have
reported no significant difference in experimental groups
compared with controls. These findings may be due to the
greater potential of the probiotics to reduce total
cholesterol and LDL-c than the levels of HDL-c and
triglyceride.
Treatment strategies to achieve optimal plasma choles-
terol levels include both lifestyle and pharmacological in-
terventions [32]. Statins, owing to their undisputed
effectiveness in reducing plasma LDL-c levels, are the
cornerstone of pharmacotherapy for hypercholesterolemia
[33]. But the use of statins can be associated with muscle-
related side effects, cognitive and memory problems, and
new-onset diabetes in a dose-related manner [5]. Also, non-
adherence and discontinuation of statin therapy often leads
to inadequate control of plasma cholesterol levels and an
increased cardiovascular risk. On the other hand, the initial
therapeutic approach to hypercholesterolemia should al-
ways include non-pharmacological measures such as: Low
dietary intake of cholesterol, saturated and “trans” fats and
increased intake of dietary fiber, as well as exercise pro-
grams suited to the patients’ physical capabilities [32].
Hence, there is a critical need to identity additional effective
hypolipidemic agents that can be used in combination with
statins and non-pharmacological interventions. Over the
past two decades, there has been a surge of interest to use
natural products for the management of hypercholester-
olemia [33]. Probiotic products are widely available in the
markets and are promoted as useful dietary supplements
for creating homeostasis of the ecosystem of microorgan-
isms in the colon which is the most metabolically active
organ in the body [10,34].
It has been suggested that probiotics may reduce blood
cholesterol in the form of cholesterol ester via the inter-
related pathways of lipid transporters [35], and promote
the excretion of the cholesterol and bile acid rather than
affecting hepatic cholesterol synthesis [28]. In addition,
another proposed mechanism of action associated with
bile salt hydrolase (BSH) activity involves the inhibition of
Niemann-Pick C1 Like 1 which is responsible for the bulk
movement of cholesterol into the enterocytes; the genetic
inactivation often results in a significant reduction of
cholesterol absorption. Beside, a study has demonstrated
that an increased circulating bile acid is correlated with a
reduction in serum LDL-c and apoB-100 which is a primary
structural protein of the atherogenic lipoproteins, and its
decrease results in reducing LDL-c serum levels [8].Subgroup analysis in the present study for duration of
intervention showed that the reduction of total cholesterol
was significantly higher in participants with intervention
duration >4 weeks. In line with our study, there are
several studies reporting significantly higher decrease in
total cholesterol in participants with intervention duration
>4weeks [10,14,16]. In another subgroup analysis per-
formed, we noticed that the reduction of total cholesterol
was significantly higher in participants who received
probiotic yogurt with the dose of 300 mg/day. Therefore,
the effect of probiotic yogurt appears to be more on lipid
profiles if longer consumption period and higher intake
are considered.
By and large, the cholesterol-lowering mechanisms of
probiotics have not yet been sufficiently elucidated.
Further studies on the large intestine which is the main
site where probiotics of fermented milk products can
function are suggested. Intestinal lactobacilli may reduce
serum cholesterol levels through the incorporation of
cholesterol into the cellular membrane to inhibit the for-
mation of intestinal cholesterol micelles, assimilation of
cholesterol by growing cells, production of BSH which
catalyzes the hydrolysis of conjugated bile salt into free
bile acids [12], and fermentation of indigestible carbohy-
drates and production of short chain fatty acids (SCFAs)
[36].
The present study has several strengths. First, there was
no time and language limitations for the inclusion of the
studies investigating the effect of probiotic yogurt on
serum lipid profiles. Second, participants of the studies
reviewed had a very low heterogeneity and were similar in
levels of primary cholesterol and health status; because
the difference in total cholesterol levels and health con-
dition at the baseline may have a significant impact on the
study results. Third, the amount of yogurt (maximum
300 mg/d) and probiotic dosage (maximum 10⁹ cfu) was
tolerable for daily consumption and could be used on the
regular daily basis in all the included studies. Fourth,
species in the Lactobacillus and Bifidobacterium genera are
the most commonly used probiotics and all studies
included in this meta-analysis used Lactobacillus aci-
dophilus and Bifidobacterium as probiotics. Fifth, partici-
pants had not used cholesterol-lowering drugs in the
studies reviewed, except for two studies in which this
issue was not mentioned [28,30]. Sixth, all crossover
studies had run in period, whether the run in period was
long enough needs further study. However, there are some
limitations to this meta-analysis. First, we analyzed both
crossover and parallel studies which were different in
terms of methods and biases. Second, there were some
deficiencies in the quality of literature which could affect
the final outcomes. In the studies we reviewed, except for
one study [8], small sample-size and short term inter-
vention time were used. This suggests that further ran-
domized clinical studies with larger sample-size and
longer intervention period to reduce possible biases are
needed. In addition, the lipid-lowering effect of probiotic
may be affected by participants’ diet and physical activ-
ities. In the studies we reviewed the participants were
Probiotic yogurt, Lipid Profile, Hypercholesterolemia 21asked not to change their regular diet and physical activity
prior to the beginning of the study. Moreover, all the
studies used the 24-h food recall questionnaire at the first
and the end of the intervention period to estimate the
individual nutrients and energy intake, except for two
studies that did not mention this issue [28,30]. In most
studies, there was no mention of physical activity
adjustment.
Finally, in most clinical studies, probiotic and conven-
tional yogurt were prepared as low-fat [4,8,28,29] and only
in two studies [17,31], they were prepared in the form of
moderate fat yogurt and full fat yogurt, respectively while
in another study, there was no explanation for the amount
of fat in yogurt [30]. Due to the few number of studies in
each group, we were unable to perform a subgroup anal-
ysis on the amount of fat in yogurt. The United States
Department of Agriculture (USDA) currently recommends
that Americans consume fat-free and low-fat dairy instead
of high-fat alternatives, and mention that “increasing the
proportion of fat-free milk consumed to meet dairy group
recommendations would decrease the amounts of sodium,
cholesterol, and saturated fatty acids”. Current evidence of
high-fat versus low-fat dairy is not conclusive, and further
studies are needed in this regard [37].Conclusion
The results of our meta-analysis show that probiotic
yogurt can significantly reduce total cholesterol and LDL-c
levels in mild to moderate hypercholesterolemic in-
dividuals. The effects of probiotic yogurt on lowering total
cholesterol were significantly higher in participants with
intervention duration >4 weeks and in participants who
received probiotic yogurt with the dose of 300 mg/day.
However, the effect of probiotic on HDL-c and triglyceride
was not statistically significant.Authors’ contributions
The authors’ responsibilities were as follows: F.SH, BP and
S.F conceived the study and designed the search strategy;
B.P and S.F conducted the study selection; B.P and S.F
conducted data extraction; B.P and S.F evaluated the risk of
bias of included studies; S.F and H.K conducted the data
analysis and interpretation of results; S.F and B.P wrote the
first draft of the manuscript; F.SH and A.D revised the
manuscript; and all authors read and approved the final
version of the manuscript.Funding source
The authors have no financial disclosure.Declaration of Competing Interest
All the authors declare that they have no conflicts of
interest.Acknowledgment
This meta-analysis was supported by Iran University of
Medical Sciences, Tehran, Iran.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.numecd.2019.10.001.References
[1] Organization WH. The World health report: 2003: shaping the
future. 2003.
[2] Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A,
et al. Cholesterol-lowering probiotics as potential biotherapeutics
for metabolic diseases2012. Experimental diabetes research; 2012.
[3] Organization WH. Global Health Observatory (GHO) data. Raised
cholesterol: situation and trends. 2008. Available at: . [Accessed 27
May 2016].
[4] Baroutkoub A, Roushanzamir M, Beglarian R, Julayi H, Sohrabi Z,
Mazloomi M, et al. Effects of probiotic yoghurt consumption on the
serum cholesterol levels in hypercholestromic cases in Shiraz,
Southern Iran. Sci Res Essays 2010;5(16):2206e9.
[5] Maningat P, Gordon BR, Breslow JL. How do we improve patient
compliance and adherence to long-term statin therapy? Curr
Atheroscler Rep 2013;15(1):291.
[6] Mannarino MR, Bianconi V, Pirro M. Commentary to “the possible
role of nutraceuticals in the prevention of cardiovascular disease”.
High Blood Pressure & Cardiovascular Prevention; 2019. p. 1e3.
[7] Pirro M, Francisci D, Bianconi V, Schiaroli E, Mannarino MR,
Barsotti F, et al. NUtraceutical TReatment for hYpercholesterolemia
in HIV-infected patients: the NU-TRY (HIV) randomized cross-over
trial. Atherosclerosis 2019;280:51e7.
[8] Jones ML, Martoni ChJ, Parent M, Prakash S. Cholesterol-lowering
efficacy of a microencapsulated bile salt hydrolase-active Lactoba-
cillus reuteri NCIMB 30242 yoghurt formulation in hyper-
cholesterolaemic adults. Br J Nutr 2012;107(10):1505e13.
[9] Thushara RM, Gangadaran S, Solati Z, Moghadasian MH. Cardio-
vascular benefits of probiotics: a review of experimental and
clinical studies. Food Func 2016;7(2):632e42.
[10] Shimizu M, Hashiguchi M, Shiga T, Tamural H, Muchizuki M. Meta-
analysis: effects of probiotic supplementation on lipid profiles in
normal to mildly hypercholesterolemic individuals. PLoS One
2015;10(10).
[11] Agerholm-Larsen L, Bell ML, Grunwald GK, Astrup A. The effect of a
probiotic milk product on plasma cholesterol: a meta-analysis of
short-term intervention studies. Eur J Clin Nutr 2000;54(11):856.
[12] Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al. Influ-
ence of consumption of probiotics on the plasma lipid profile: a
meta-analysis of randomised controlled trials. Nutr Metab Car-
diovasc Dis 2011;21(11):844e50.
[13] Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a
meta-analysis of randomized controlled trials. Medicine 2015;
94(43).
[14] Sun J, Buys N. Effects of probiotics consumption on lowering lipids
and CVD risk factors: a systematic review and meta-analysis of
randomized controlled trials. Ann Med 2015;47(6):430e40.
[15] Sharma S, Kurpad AV, Puri S. Potential of probiotics in hypercho-
lesterolemia: a meta-analysis. Indian J Public Health 2016;60(4):
280.
[16] Wang L, Gue MJ, Gao Q, Yang JF, Yang L, Pang XL, et al. The effects
of probiotics on total cholesterol A meta-analysis of randomized
controlled trials. Medicine 2018;97(5).
[17] Kiessling G, Schneider J, Jahreis G. Long-term consumption of
fermented dairy products over 6 months increases HDL choles-
terol. Eur J Clin Nutr 2002;56(9):843e9.
[18] Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M,
et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015: elaboration and explana-
tion. Bmj 2015;349:g7647.
22 B. Pourrajab et al.[19] Higgins JP. Cochrane handbook for systematic reviews of in-
terventions version 5.0. 1. The Cochrane Collaboration; 2008.
http://www.cochrane-handbook.org.
[20] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance
from the median, range, and the size of a sample. BMC Med Res
Methodol 2005;5(1):13.
[21] Fatahi S, Namazi N, Larijani B, Azadbakht L. The association of
dietary and urinary sodium with bone mineral density and risk of
osteoporosis: a systematic review and meta-analysis. J Am Coll
Nutr 2018;37(6):522e32.
[22] Iyengar S, Greenhouse J. Sensitivity analysis and diagnostics. Hand-
book of research synthesis and meta-analysis. 2009. p. 417e33.
[23] Nct. Efficacy of Cardioviva probiotic yogurt formulation. 2010.
https://clinicaltrials.gov/show/nct01185795.
[24] Sadrzadeh-Yeganeh H, Elmadfa I, Djazayeri A, Jalali M, Heshmat R,
Chamary M. The effects of probiotic and conventional yoghurt on
lipid profile in women. Br J Nutr 2010;103(12):1778e83.
[25] Ivey KL, Hodgson JM, Kerr DA, Thompson PL, Stojceski B, Prince RL.
The effect of yoghurt and its probiotics on blood pressure and
serum lipid profile; a randomised controlled trial. Nutr Metab
Cardiovasc Dis 2015;25(1):46e51.
[26] Fabian E, Elmadfa I. Influence of daily consumption of probiotic
and conventional yoghurt on the plasma lipid profile in young
healthy women. Ann Nutr Metabol 2006;50(4):387e93.
[27] Agerbaek M, Gerdes L, Richelsen B. Hypocholesterolaemic effect of
a new fermented milk product in healthy middle-aged men. Eur J
Clin Nutr 1995;49(5):346e52.
[28] Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A,
et al. Effects of milk products fermented by Bifidobacterium lon-
gum on blood lipids in rats and healthy adult male volunteers. J
Dairy Sci 2003;86(7):2452e61.
[29] Anderson JW, Gilliland SE. Effect of fermented milk (yogurt)
containing Lactobacillus acidophilus L1 on serum cholesterol in
hypercholesterolemic humans. J Am Coll Nutr 1999;18(1):43e50.[30] Ataie-Jafari A, Hosseini S, Alavi-Majid H, Tahbaz F. Effects of milk
replacement with regular yogurt and probiotic yogurt on blood
lipid profiles of hypercholesterolemic and normocholesterolemic
individuals. Iran J Diabetes & Lipid Disord 2007;7(2):239e44.
E24.
[31] Ataie-Jafari A, Hosseini S, Alavi-Majid H, Tahbaz F. Cholesterol-
lowering effect of probiotic yogurt in comparison with ordinary
yogurt in mildly to moderately hypercholesterolemic subjects.
Ann Nutr Metabol 2009;54(1):22e7.
[32] Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F,
Rivellese AA. Joint position statement on “nutraceuticals for the
treatment of hypercholesterolemia” of the Italian society of dia-
betology (SID) and of the Italian society for the study of arterio-
sclerosis (SISA). Nutr Metab Cardiovasc Dis 2017;27(1):2e17.
[33] Johnston T, Korolenko TA, Pirro M, Sahebkar A. Preventing car-
diovascular heart disease: promising nutraceutical and non-
nutraceutical treatments for cholesterol management. Pharmacol
Res 2017;120:219e25.
[34] Wichansawakun S, Buttar HS. Chapter 32 - antioxidant diets and
functional foods promote healthy aging and longevity through
diverse mechanisms of action. In: Singh RB, Watson RR,
Takahashi T, editors. The role of functional food security in global
health. Academic Press; 2019. p. 541e63.
[35] Liong M-T, Dunshea FR, Shah NP. Effects of a synbiotic containing
Lactobacillus acidophilus ATCC 4962 on plasma lipid profiles and
morphology of erythrocytes in hypercholesterolaemic pigs on
high-and low-fat diets. Br J Nutr 2007;98(4):736e44.
[36] St-Onge M-P, Farnworth ER, Jones PJ. Consumption of fermented
and nonfermented dairy products: effects on cholesterol concen-
trations and metabolism. Am J Clin Nutr 2000;71(3):674e81.
[37] Yu E, Hu FB. Dairy products, dairy fatty acids, and the prevention
of cardiometabolic disease: a review of recent evidence. Curr
Atheroscler Rep 2018;20(5):24.
